Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545820 | 1.00 | KMT2A (0.43) | KMT2AMEN1ABCG2CTSDAPP | |
| SCHEMBL7548338 | 1.00 | KMT2A (0.43) | KMT2AMEN1ABCG2CTSDAPP | |
| SCHEMBL7545814 | 1.00 | KMT2A (0.43) | KMT2AMEN1ABCG2CTSDAPP | |
| SCHEMBL7687734 | 0.99 | KMT2A (0.44) | KMT2AMEN1ABCG2CTSDAPP | |
| SCHEMBL7544561 | 0.99 | KMT2A (0.44) | KMT2AMEN1ABCG2CTSDAPP | |
| SCHEMBL7549124 | 0.99 | KMT2A (0.44) | KMT2AMEN1ABCG2CTSDAPP | |
| SCHEMBL7544558 | 0.99 | KMT2A (0.44) | KMT2AMEN1ABCG2CTSDAPP | |
| SCHEMBL7544564 | 0.99 | KMT2A (0.44) | KMT2AMEN1ABCG2CTSDAPP | |
| SCHEMBL7695200 | 0.92 | KMT2A (0.45) | KMT2AMEN1ABCG2APPSIGMAR1 | |
| SCHEMBL7645477 | 0.91 | KMT2A (0.45) | KMT2AMEN1ABCG2APPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082263-A1 | Heterocycle derivatives as PPAR-gamma agonists | ADVANCED SYNTECH LLC | 2002-06-27 | — | — | US | claimed |
| US-20020082263-A1 | Heterocycle derivatives as PPAR-gamma agonists | ADVANCED SYNTECH LLC | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082263-A1 | Heterocycle derivatives as PPAR-gamma agonists | PPARG, PPARD, PPARA | KMT2A 2543/4885MEN1 4629/4885ABCG2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.